Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Doximity

Doximity, Inc. develops an online healthcare resource and interactive platform. The Company cloud-based platform enables its members to collaborate with their colleagues, securely coordinate patient care, and conducts virtual patient visits. Doximity serves customers in the United States.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Doximity surpasses Q4 revenue expectations and eyes continued growth

Doximity's Q4 2023 performance exceeded expectations, showcasing strong financial metrics and strategic investments. The company's outlook for Q1 2024 indicates continued growth, with a focus on topline expansion and product innovation. While facing challenges in pricing strategies and competitive landscape, Doximity is well-positioned to capitalize on opportunities in the healthcare technology sector.

Doximity reports strong Q1 results but lowers 2024 guidance

Doximity delivered strong financial performance in Q1, but challenges in upsell close rates led to a downward revision in annual guidance. The company's focus on innovation, expansion, and shareholder value, along with a cautious outlook for the remainder of the year, presents a mixed picture of opportunities and challenges for investors.

Doximity reports strong Q3 earnings, eyes growth amid product challenges

Doximity's Q3 performance demonstrated resilience and growth potential despite challenges in meeting annual guidance due to product delays.
The company's focus on innovation, strong client relationships, and strategic investments position it well for future growth and market leadership.
With a commitment to R&D, expanding product offerings, and maintaining pricing discipline, Doximity aims to capitalize on opportunities and navigate challenges for sustained success.

Doximity surpasses Q4 revenue targets, poised for growth and innovation

Doximity's Q4 performance exceeded expectations, with robust revenue growth, strong margins, and strategic investments in new products and talent.
While facing challenges like flat growth in certain segments and pricing adjustments, the company is well-positioned to capitalize on opportunities in network expansion and technology innovation.
With a focus on enhancing user experience, driving engagement, and optimizing revenue streams, Doximity is poised for continued success and value creation for shareholders.
The company's financial health, innovative product offerings, and market positioning indicate a promising outlook for sustained growth and competitive advantage in the healthcare technology sector.

Doximity surpasses Q1 revenue expectations, faces upsell challenges

Doximity's Q1 performance was strong, but challenges in upsells prompted a staff reduction and revised guidance. The company is optimistic about long-term growth, leveraging new products and a self-serve ad platform for future success.

Doximity beats Q2 expectations, eyes growth amidst market uncertainties

Doximity's strong Q2 performance exceeded revenue and EBITDA guidance, driven by record physician engagement and new product success.
While facing market uncertainties and competition challenges, the company sees opportunities in pricing strategies and continued growth.
Investments in high-touch services, Telehealth, and video products are paying off, with a focus on enhancing client offerings.
Integration with IQVIA for real-time ROI analysis positions Doximity for future growth and client value creation.

Doximity beats Q3 revenue, eyes growth through AI products

Doximity's Q3 performance exceeded expectations with strong revenue and margin growth. The company faces challenges with elongated sales cycles but has opportunities for growth through AI products and new modules. Overall, Doximity's competitive position remains strong in the market.

Doximity exceeds Q4 revenue, eyes mid-teens growth post-COVID

Doximity's Q4 earnings call highlighted strong financial performance, customer satisfaction initiatives, and growth opportunities in digital marketing and new business segments. While facing challenges in growth slowdowns and market uncertainties, the company is leveraging strengths in optimized margins, visibility into revenue guidance, and customer commitment to drive future success.

Doximity excels in Q1 2025, driving growth through client value

Doximity's Q1 2025 performance reflects strong revenue growth, operational efficiency, and client value proposition.
The company's focus on innovation, customer engagement, and strategic insights positions it well for sustained growth.
Despite challenges, Doximity's proactive approach to industry dynamics and growth opportunities bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

The mean of analysts' price targets for Doximity (DOCS) points to a 32.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Doximity (DOCS)? Wall Street Analysts Think 32%

CrowdStrike

NVIDIA

Block

Upstart Holdings

Don't overlook these potentially huge tech trends.

5 Unstoppable Trends to Invest $10,000 in Right Now

Amgen

Novocure

Healthcare is the smart play in this bear market. Here's why these three Fool.com contributors like Doximity, Amgen, and Novocure.

Scared of the Bear? Buy These 3 Healthcare Stocks

SAN FRANCISCO, Feb. 16, 2022 /PRNewswire/ -- Over 73% of patients plan to continue using telemedicine platforms post-pandemic, according to Doximity's second edition of its State of Telemedicine Repor t , which was released today. As part of the report, Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, analyzed adoption of telemedicine across its physician user base from January 2020 through June 2021 and conducted a study of patients' experiences with telemedicine during the same time frame.

Doximity's New Report Finds Adoption of Telemedicine Growing, Majority of Patients Plan for Virtual Care Post-Pandemic

The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Doximity (DOCS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Doximity (DOCS) Could Rally 36%: Here's is How to Trade

Patient investors who buy this unique healthcare stock now could see market-beating returns.

3 Reasons to Buy Doximity in 2022 and Never Sell

Doximity announced financial results that make its long-term future look bright.

1 Growth Stock's Dominant Grip Just Got Stronger

Advertisers are flocking to the social-media network for doctors.

Why Doximity Stock Soared Today

Shares of virtual healthcare company Doximity are up more than 20% today after the company announced a strategic acquisition. The post DOCS Stock Alert: What to Know About the Deal Sending Doximity Up 20% appeared first on InvestorPlace.

DOCS Stock Alert: What to Know About the Deal Sending Doximity Up 20%

Doximity Inc DOCS posted Q3 FY22 sales of $97.9 million, an increase of 67% Y/Y, beating the consensus of $86.27 million. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Why Doximity Shares Are Trading Higher Premarket Today?

Doximity, Inc. (DOCS) CEO Jeff Tangney on Q3 2022 Results - Earnings Call Transcript

The stock price of Doximity, Inc. (NYSE: DOCS) increased by 8.35% after hours. This is why it happened.

Doximity (DOCS) Stock: Why The Price Increased After Hours

SAN FRANCISCO, Feb. 8, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that it has acquired Amion, a leading on-call physician scheduling site. Amion manages nearly 200,000 physician schedules at thousands of hospitals, including 18 of the top 20.

Doximity to Acquire Amion, Leader in Physician Scheduling

SAN FRANCISCO, Feb. 8, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results for the fiscal 2022 third quarter ended December 31, 2021. "We had a strong Q3 led by our existing clients as our net revenue retention rate hit 171%," said Jeff Tangney, co-founder & CEO at Doximity.

Doximity Announces Fiscal 2022 Third Quarter Financial Results

SAN FRANCISCO, Feb. 8, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, announced today that Doximity Dialer, its popular telehealth platform, has been named 2022 'Best in KLAS' in the Telehealth - Video Conferencing Platforms segment. The complete 2022 Best in KLAS: Software & Services report can be found here.

Doximity Dialer is Ranked #1 in the 2022 Best in KLAS report for Telehealth Video Conferencing Platform

Affimed

Here's why our roundtable is excited about Doximity, Novocure, and Affimed.

3 Amazing Stocks That Are 60% Off Their Highs

Its future is promising, but there are still a few obstacles to overcome.

2 Green Flags and 2 Red Flags for Doximity Stock

Coinbase

These two industry leaders have fallen far off their all-time highs, and now might be the perfect time to invest.

Bargain Shopping? 2 Growth Stocks Down 50% to 58% to Buy in 2022

Doximity has a dominant hold on this lucrative niche.

My Top Growth Stock to Buy on Sale for 2022

SAN FRANCISCO, Jan. 18, 2022/ /PRNewswire/ -- Doximity, Inc. (NYSE:DOCS) will announce financial results for its third quarter which ended December 31, 2021 after market close on February 8, 2022. Doximity will host a conference call and webcast that day at 2:00 p.m.

Doximity to Release Fiscal 2022 Third Quarter Results on February 8, 2022

Doximity has cultivated a strong brand name among healthcare professionals.

This Monster Growth Stock Could Make You Richer in 2022 (and Beyond)

Why Doximity Stock Plummeted 26% in December

Tivity Health

TVTY vs. DOCS: Which Stock Is the Better Value Option?

TVTY or DOCS: Which Is the Better Value Stock Right Now?

DermTech Inc

These two stocks could provide life-changing returns in 10 years.

Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade

Coupang

These two young companies are working to expand on the market dominance they already have in their respective industries.

News for Doximity Stock (DOCS)